An abstract titled, “GLP-1 Agonists Can Prevent Liver Disease Progression in Patients with Metabolic and Alcohol-Associated Liver Disease (MetALD),” was published in Digestive Disease Week and subsequently presented by authors Amir Gougol, C. William Pike, Niloufar Khanna, and Paul Yien Kwo. Dr. Pike is affiliated with Atropos Health.
Short Summary:
GLP-1 agonists (GLP1a) have shown effectiveness in control of certain components of metabolic dysfunction. Also, recent animal studies suggested GLP-1a can reduce alcohol consumption and addictive behavior. No human study has investigated the outcomes of GLP-1a use in patients with MetALD. This study aimed to assess the benefit of GLP-1a to prevent hepatic decompensation in patients with MetALD.
Key Conclusions:
GLP1a is a promising therapy in patients diagnosed with steatotic liver disease and may also improve outcomes in those with MetALD. If these results are confirmed, randomized clinical trials are warranted to confirm the beneficial effect of GLP1a in this population.
To learn how Atropos Health can accelerate and supplement your research with Real-World Evidence (RWE), email us: sales@atroposhealth.com